New research published by investigators at The University of California Los Angeles highlights the impact Transpara can have in helping to detect breast cancer sooner.
The researchers used ScreenPoint Medical’s Transpara Detection algorithm in their research to determine if it could detect subtle signs of cancer that were missed by radiologists during initial screenings, or at least flag them as suspicious. UCLA Newsroom notes that Transpara was “able to identify mammographically visible types of interval cancers, or ones that develop between screenings, earlier by flagging them at the time of screening. These include tumors that are visible on mammograms but not detected by radiologists, or have very subtle signs on mammography that are easy to miss because the signs were faint or arguably below the level of detection by the human eye.”
Key highlights from the study include:
● The researchers found that Transpara Detection flagged 76% of the mammograms that had been originally read as normal by radiologists but were later linked to an interval breast cancer.
● Transpara flagged 90% of missed reading error cases where the cancer had been visible on the mammogram but missed or misinterpreted by the radiologist.
As noted in the writeup, Transpara “shows potential to serve as a valuable second set of eyes, especially for the types of cancers that are the hardest to catch early. This is about giving radiologists better tools and giving patients the best chance at catching cancer early, which could lead to more lives saved.”
A researcher on the study, Dr. Hannah Milch, also shared more about the study on a recent episode of The Imaging Wire Show. Watch full interview below:
